

janiecbros/E+ via Getty Images
The healthcare sector (NYSEARCA:XLV) has seen “the fruits of its labor” in higher earnings growth and help from advancing technologies, and analysts see improving investor sentiment from underweight positions.
According to State Street Global Advisors SPDR in their Sector & Equity Compass Report for Q2, the healthcare sector (XLV) “fits the bill with its high-quality characteristics, low volatility, and defensive operations,” and “is one of the few sectors that has better long-term performance in Europe than in the US.”
Analysts said that European pharmaceutical and biotech companies have promising research and development productivity with several potential drug approvals in cancer, neurology, rare diseases, and immunology in coming years.
“Health Care (XLV) has been benefiting from transformational emerging technologies for several years without much fanfare from investors,” analysts said. “The use of AI could be significant to all industries in this sector, the largest being drug discovery.”
In addition, research and development to launch new treatments should have huge cost benefits for pharmaceutical and biotech companies in the upcoming years, with drug candidates becoming much cheaper and more efficient, raising the hit rate of experimental medicines.
Competition, however, is keeping much of this work still in the shadows, analysts said.
Healthcare reform and impacts to pharmaceuticals as it relates to coverage is currently in focus as the November U.S. election looms.
“Republicans have generally advocated for market-orientated solutions and opposed government intervention in the sector,” the report said. “Democrats often advocate for expanding access to healthcare whilst limiting pricing power. While we are not overly concerned, do expect some volatility.”
Top European holdings: Novo Nordisk A/S Class B (NVO), AstraZeneca Plc. (AZN), Novartis AG (NVS), Roche Holding Ltd. (OTCQX:RHHBY), Sanofi (SNY).